Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 10/20 | 0.65 |
| ▸ | THRB | P10828 | 10/20 | 0.65 |
| ▸ | THRA | P10827 | 9/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1525944 | 0.85 | THRB (0.63) | PCNATHRBTHRAPOLBHIF1A | |
| SCHEMBL6473141 | 0.84 | FFAR1 (0.58) | PCNATHRBTHRAPOLBHIF1A | |
| Thyropropic Acid SCHEMBL310201 | 0.79 | PCNA (1.00) | PCNATHRBTHRAPOLBHIF1A | |
| SCHEMBL4607653 | 0.77 | THRB (0.48) | PCNATHRBTHRAPOLBHIF1A | |
| SCHEMBL12012506 | 0.77 | PCNA (0.59) | PCNATHRBTHRAPOLBHIF1A | |
| SCHEMBL6041111 | 0.77 | THRB (0.40) | PCNATHRBTHRAPOLBHIF1A | |
| SCHEMBL4238467 | 0.77 | THRB (0.73) | PCNATHRBTHRAPOLBHIF1A | |
| 3,5-Diiodothyropropionic Acid SCHEMBL1501771 | 0.75 | PCNA (1.00) | PCNATHRBTHRAPOLBHIF1A | |
| SCHEMBL12440046 | 0.75 | PCNA (0.69) | PCNATHRBTHRAPOLBHIF1A | |
| SCHEMBL8733106 | 0.74 | THRB (0.39) | PCNATHRBTHRAPOLBHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2662079-A1 | Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells | Ordway Research Institute, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| EP-1594480-A4 | METHOD TO TREAT CHRONIC HEART FAILURE AND/OR ELEVATED CHOLESTEROL LEVELS | UNIV ARIZONA (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2005123099-A2 | METHODS AND COMPOSITIONS FOR ACCELERATING ALCOHOL METABOLISM | ENZYMEDIX, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050272817-A1 | Dermatological use and a dermatological preparation | HEINO PEKKA | 2005-12-08 | — | — | US | claimed |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ENZYMEDIX | 2005-12-08 | — | — | US | claimed |
| EP-1594480-A1 | METHOD TO TREAT CHRONIC HEART FAILURE AND/OR ELEVATED CHOLESTEROL LEVELS | The Arizona Board of Regents on Behalf of the University of Arizona (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2004073694-A1 | METHOD TO TREAT CHRONIC HEART FAILURE AND/OR ELEVATED CHOLESTEROL LEVELS | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2004-09-02 | — | — | WO | claimed |
| US-6716877-B2 | Method to treat chronic heart failure and/or elevated cholesterol levels | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2004-04-06 | — | — | US | claimed |
| US-20030147815-A1 | Method to treat chronic heart failure and/or elevated cholesterol levels | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE | 2003-08-07 | — | — | US | claimed |
| US-20030144359-A1 | Dermatological use and a dermatological preparation | HEINO, PEKKA (FI) | 2003-07-31 | — | — | US | claimed |
| EP-1274416-A1 | DERMATOLOGICAL USE AND A DERMATOLOGICAL PREPARATION | Ipsat Therapies Oy (FI) | 2003-01-15 | — | — | EP | claimed |
| WO-2001076589-A1 | DERMATOLOGICAL USE AND A DERMATOLOGICAL PREPARATION | IPSAT THERAPIES OY (FI) | 2001-10-18 | — | — | WO | claimed |
| US-20090131380-A1 | Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof | HEINO PEKKA | 2009-05-21 | — | — | US | disclosed |
| EP-1594480-A4 | METHOD TO TREAT CHRONIC HEART FAILURE AND/OR ELEVATED CHOLESTEROL LEVELS | UNIV ARIZONA (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1594480-A4 | METHOD TO TREAT CHRONIC HEART FAILURE AND/OR ELEVATED CHOLESTEROL LEVELS | UNIV ARIZONA (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2005123099-A2 | METHODS AND COMPOSITIONS FOR ACCELERATING ALCOHOL METABOLISM | ENZYMEDIX, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20030147815-A1 | Method to treat chronic heart failure and/or elevated cholesterol levels | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE | 2003-08-07 | — | — | US | disclosed |
| US-20030144359-A1 | Dermatological use and a dermatological preparation | HEINO, PEKKA (FI) | 2003-07-31 | — | — | US | disclosed |
| EP-1274416-A1 | DERMATOLOGICAL USE AND A DERMATOLOGICAL PREPARATION | Ipsat Therapies Oy (FI) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001076589-A1 | DERMATOLOGICAL USE AND A DERMATOLOGICAL PREPARATION | IPSAT THERAPIES OY (FI) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272817-A1 | Dermatological use and a dermatological preparation | TPO, TYR, TRHDE | PCNA 442/4885THRB 26/4885THRA 17/4885 |
| US-20030144359-A1 | Dermatological use and a dermatological preparation | TPO, TYR, TRHDE | PCNA 442/4885THRB 26/4885THRA 17/4885 |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ADH1A, ADH1C, ADH5 | PCNA 1377/4885THRB 2655/4885THRA 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.